Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-39439335 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | JNJ-39439335 2 x 5 mg tablets once daily for 21 days |
| 002 | EXPERIMENTAL | JNJ-39439335 2 x 25 mg tablets once daily for 21 days |
| 003 | OTHER | Naproxen 500 mg capsule every 12 hours for 21 days |
| 004 | PLACEBO_COMPARATOR | Placebo Placebo tablet/capsule every 12 hours for 21 days |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo tablet/capsule every 12 hours for 21 days |
| JNJ-39439335 | DRUG | 2 x 25 mg tablets once daily for 21 days |
| Naproxen | DRUG | 500 mg capsule every 12 hours for 21 days |
| JNJ-39439335, Placebo | DRUG | - |
Inclusion Criteria: * Nonsmoker \>= 6 months prior to first dose * body mass index (BMI) \<= 36 kg/m2 * Meet American College of Rheumatology (ACR) clinical classification criteria for osteoarthritis of knee by meeting at least 3 of the following: age \> 50, morning stiffness \< 30 minutes, crepitu...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
JNJ-39439335 is an investigational small molecule being studied for the treatment of knee osteoarthritis pain. It has been evaluated in Phase 1 clinical trials in patients with osteoarthritis of the knee, as well as in an exploratory pain study using a thermal-grill experimental model. It is not approved for any indication.
JNJ-39439335 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the Phase 1 clinical program evaluating the compound in knee osteoarthritis pain and in an experimental pain model.
JNJ-39439335 is in Phase 1 clinical development. It is an investigational small molecule and has not been approved by the FDA or any other regulatory authority. Two Phase 1 trials have been completed, and no active trials are currently listed.
JNJ-39439335 has been studied in two completed Phase 1 trials. NCT01343303 was a multiple-dose study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in 43 patients with knee osteoarthritis in South Africa. NCT01006304 was an exploratory study assessing pain relief using a thermal-grill experimental model in 12 healthy male volunteers.